TCTMD - tctmd.com
WEBGiven the growing prevalence of heart failure worldwide, we recognize a clear mandate for developing new monitoring strategies and treatment options to increase survival, decrease hospitalizations, and improve quality of life — and for achieving these goals via a variety of potential interventions that target the various contributors to heart ...
Polypills Show Promise in Diverse Hypertensive Patient Groups
WEBAug 31, 2024 · The mean BP measured in clinic was 138/86 mm Hg. Individuals with a systolic BP on home measurement of 130-154 mm Hg were randomized to the triple quarter dose, triple half dose, or placebo. At 6 weeks, 70% of patients in the triple half-dose group, 65% in the triple quarter-dose group, and 37% in the placebo group achieved a …
FDA Approves First Transcatheter Tricuspid Valve Replacement …
WEBFeb 2, 2024 · In a surprise early-morning announcement, Edwards Lifesciences said the US Food and Drug Administration has approved the company’s Evoque tricuspid valve replacement system for the treatment of tricuspid regurgitation (TR). The approval is the first in the United States for a transcatheter tricuspid device. …
TCT 2023 - TCTMD.com
WEBOct 23, 2023 · It Isn’t Always That Easy: Challenging Access Strategies, Including Intravascular Lithotripsy. Presenter: Ethan Korngold. Presentation TCT 2023.
‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry
WEBJan 10, 2020 · With a list price of $225,000 per year, tafamidis is the most expensive cardiovascular drug on the market. Mathew Maurer, MD (Columbia University Irving Medical Center, New York, NY), who published his views along with Jerry Gurwitz, MD (University of Massachusetts Medical School, Worcester), January …
More Trial Evidence Supports Tenecteplase for Acute Stroke …
WEBMay 21, 2024 · Later in the meeting, Shuya Li, MD (Beijing Tiantan Hospital, Capital Medical University, China), presented the results of the ORIGINAL trial, a phase III study designed to support regulatory approval of tenecteplase for acute stroke in China. At 55 sites across the country, investigators randomized 1,489 patients (mean age 65 …
Both SGLT2 and GLP-1 Drugs Help Heart and Kidneys in Type 2 …
WEBAug 19, 2024 · For patients with type 2 diabetes and confirmed CKD, again both SGLT2 inhibitors and GLP-1 receptor agonists are class 1 recommendations. “SGLT2 inhibitors would have a slight preference in the setting of CKD, but those patients also should be on both SGLT2 inhibitors and GLP-1 receptor agonists independent of …
Micra Leadless Pacemaker Performs Well Through 5 Years
WEBMar 6, 2024 · The Micra VR leadless pacemaker (Medtronic) continues to have a good safety and efficacy profile through the 5-year mark, according to real-world registry data. Rates of major complications and revisions were both under 5%, and no patients required device removal for infection. Moreover, as researchers led by …
New AHA Guidance on Omega-3 Fatty Acids for High Triglycerides
WEBAug 21, 2019 · For managing hypertriglyceridemia (200-499 mg/dL), the AHA experts state that prescription-strength omega-3 fatty acids, either with eicosapentaenoic acid (EPA) or EPA plus docosapentaenoic acid (DHA), would be expected to yield a 20% to 30% reduction in triglycerides without any increase in LDL cholesterol.
New ARISTOTLE Data ‘Reassuring’ on Lower Apixaban Dose
WEBMar 12, 2020 · In A-fib patients selected using established dose-reduction criteria, the 2.5-mg twice daily dose of apixaban (Eliquis; Bristol-Myers Squibb) provides protection against stroke and death versus warfarin that is consistent with the effects of the standard 5.0-mg twice daily dose in the rest of the patients, despite reduced exposure to the drug in the blood, data from ARISTOTLE indicate.